Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 4

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Other hematologic neoplasm 1

Conditions

Breast Neoplasms 3Cardiotoxicity 2Hematologic Neoplasms 1Heart Failure 1Cardiomyopathies 1Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Has results × Carvedilol × Clear all
NCT04023110 2025-10-09

CCTGuide Pilot

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
68 enrolled 20 charts
Breast

Breast Neoplasms, Heart Failure, Cardiomyopathies, Cardiotoxicity

NCT02717507 2025-04-23

Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

Children's Oncology Group

Phase 2 Completed
196 enrolled 26 charts
Other hematologic neoplasm

Hematologic Neoplasms

NCT02177175 2022-07-12

Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
82 enrolled 13 charts
Breast

Breast Neoplasms

NCT01009918 2021-03-30

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

University of South Florida

Phase 2 Completed
468 enrolled 16 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡